DK0607775T3 - Anvendelse af leflunomid til inhibering af interleukin 1 beta - Google Patents
Anvendelse af leflunomid til inhibering af interleukin 1 betaInfo
- Publication number
- DK0607775T3 DK0607775T3 DK94100013T DK94100013T DK0607775T3 DK 0607775 T3 DK0607775 T3 DK 0607775T3 DK 94100013 T DK94100013 T DK 94100013T DK 94100013 T DK94100013 T DK 94100013T DK 0607775 T3 DK0607775 T3 DK 0607775T3
- Authority
- DK
- Denmark
- Prior art keywords
- beta
- leflunomide
- inhibit interleukin
- interleukin
- inhibit
- Prior art date
Links
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 title abstract 2
- 102000003777 Interleukin-1 beta Human genes 0.000 title abstract 2
- 108090000193 Interleukin-1 beta Proteins 0.000 title abstract 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000681 leflunomide Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4300277 | 1993-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0607775T3 true DK0607775T3 (da) | 1999-08-16 |
Family
ID=6477853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94100013T DK0607775T3 (da) | 1993-01-08 | 1994-01-03 | Anvendelse af leflunomid til inhibering af interleukin 1 beta |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5556870A (enExample) |
| EP (1) | EP0607775B1 (enExample) |
| JP (1) | JPH06234635A (enExample) |
| AT (1) | ATE174218T1 (enExample) |
| DE (1) | DE59407413D1 (enExample) |
| DK (1) | DK0607775T3 (enExample) |
| ES (1) | ES2124800T3 (enExample) |
| GR (1) | GR3029491T3 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6335356B1 (en) | 1994-01-07 | 2002-01-01 | Sugen, Inc. | Method of treating a patient by parenteral administration of a lipophilic compound |
| US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
| US5519042A (en) * | 1994-01-13 | 1996-05-21 | Hoechst Aktiengesellschaft | Method of treating hyperproliferative vascular disease |
| US5721277A (en) * | 1995-04-21 | 1998-02-24 | Sugen, Inc. | Compounds and methods for inhibiting hyper-proliferative cell growth |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US6011051A (en) * | 1996-07-31 | 2000-01-04 | Hoechst Aktiengesellschaft | Use of isoxazole and crotonamide derivatives for the modulation of apoptosis |
| DE19711800A1 (de) * | 1997-03-21 | 1998-09-24 | Hoechst Ag | Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung |
| US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
| DE59800287D1 (de) * | 1997-08-08 | 2000-11-09 | Aventis Pharma Gmbh | Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid |
| US7691890B2 (en) | 1998-03-11 | 2010-04-06 | James W. Williams | Anti-viral uses of leflunomide products |
| ATE382349T1 (de) * | 1998-03-11 | 2008-01-15 | Williams James W | Antivirale verwendungen von leflunomid produkten |
| DE19847823A1 (de) | 1998-10-16 | 2000-04-20 | Aventis Pharma Gmbh | Substituierte Thiadiazolsulfonamide |
| DE19860802A1 (de) * | 1998-12-30 | 2000-10-26 | Virgene Pharmaceuticals Ag | Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren |
| CA2390857A1 (en) * | 1999-11-30 | 2001-06-14 | Fatih M. Uckun | Inhibitors of collagen-induced platelet aggregation |
| US6589992B2 (en) | 1999-11-30 | 2003-07-08 | Parker Hughes Institute | Inhibiting collagen-induced platelet aggregation |
| EP1473035A1 (en) * | 2000-02-15 | 2004-11-03 | Teva Pharmaceutical Industries Ltd. | Leflunomide of high purity |
| HRP20020671A2 (en) | 2000-02-15 | 2004-12-31 | Teva Pharma | A method for synthesizing leflunomide |
| WO2009133141A2 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
| US10813917B2 (en) | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
| SMT202100127T1 (it) * | 2009-12-11 | 2021-05-07 | Medregen Llc | Metodi di trattamento che utilizzano mobilizzatori di cellule staminali e agenti immunosoppressori |
| JP5820476B2 (ja) | 2010-08-24 | 2015-11-24 | アルギアックス ファルマコウティカルス ゲーエムベーハーＡＬＧＩＡＸ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＧｍｂＨ | レフルノミドおよびマロノニトリラマイドの新規の使用 |
| US11096934B2 (en) * | 2015-09-01 | 2021-08-24 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing hematological cancers |
| WO2018096538A1 (en) * | 2016-11-23 | 2018-05-31 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| RU2142937C1 (ru) * | 1990-05-18 | 1999-12-20 | Хехст АГ | Амиды органических кислот, способ их получения и фармацевтическая композиция |
| ATE197646T1 (de) * | 1990-08-06 | 2000-12-15 | Chiron Corp | Verfahren zum nachweis von cytokinkonvertasehemmern |
| WO1992016226A1 (en) * | 1991-03-19 | 1992-10-01 | Smithkline Beecham Corporation | Il-1 inhibitors |
| AU7629594A (en) * | 1993-07-21 | 1995-02-20 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
-
1994
- 1994-01-03 DK DK94100013T patent/DK0607775T3/da active
- 1994-01-03 DE DE59407413T patent/DE59407413D1/de not_active Expired - Lifetime
- 1994-01-03 ES ES94100013T patent/ES2124800T3/es not_active Expired - Lifetime
- 1994-01-03 EP EP94100013A patent/EP0607775B1/de not_active Expired - Lifetime
- 1994-01-03 AT AT94100013T patent/ATE174218T1/de active
- 1994-01-07 JP JP6000425A patent/JPH06234635A/ja active Pending
-
1995
- 1995-03-28 US US08/411,849 patent/US5556870A/en not_active Expired - Lifetime
-
1999
- 1999-02-25 GR GR990400587T patent/GR3029491T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06234635A (ja) | 1994-08-23 |
| EP0607775A2 (de) | 1994-07-27 |
| GR3029491T3 (en) | 1999-05-28 |
| EP0607775B1 (de) | 1998-12-09 |
| EP0607775A3 (enExample) | 1994-08-31 |
| ES2124800T3 (es) | 1999-02-16 |
| DE59407413D1 (de) | 1999-01-21 |
| US5556870A (en) | 1996-09-17 |
| ATE174218T1 (de) | 1998-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0607775T3 (da) | Anvendelse af leflunomid til inhibering af interleukin 1 beta | |
| SE7903186L (sv) | Cerebralverksamt medel | |
| DK0607776T3 (da) | Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa | |
| ATE156482T1 (de) | 1,4,5-triphenyl-pyrazolverbindungen zur behandlumg von entzündungen und entzündungsverwandten störungen | |
| KR100344712B1 (ko) | 알러지성및염증성질환의치료에유용한화합물 | |
| FI935585A0 (fi) | Pyrrolopyrimidiner | |
| DE122006000010I1 (de) | Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3- Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten | |
| PT809636E (pt) | Isoxazoles substituidos utilizaveis para o tratamento de inflamacoes | |
| DK0607777T3 (da) | Anvendelse af leflunomid til inhibering af interleukin 8 | |
| FI935777A0 (fi) | Inhibitorer foer HIV-proteas anvaendbara vid behandling av AIDS | |
| ATE124681T1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
| MD960168A (ro) | Metodă şi compuşi pentru tratamentul infecţiilor virale | |
| DK472688A (da) | Anvendelse af bezafibrat til behandling af diabetes | |
| BR9304780A (pt) | Composto, processo para preparar o composto, composição farmacêutica e uso | |
| DK0607774T3 (da) | Anvendelse af leflunomid til inhibering af interleukin 1 alfa | |
| FI904475A7 (fi) | Tymopentiiniä sisältävät koostumukset ihosairauksien hoitamiseksi paik allisesti | |
| DK149590C (da) | Analogifremgangsmaade til fremstilling af 2-aryl-3,4-diaza-bicyclo(4,1,0)hepten-(2)-on-(5)-forbindelser | |
| BE858467A (fr) | Compositions stabilisees d'acides isocyanatosulfoniques aromatiques | |
| TR23391A (tr) | Yeni tiofen bilesikleri ve bunlarin hazirlanmasi | |
| DK4389A (da) | Isoxazoler med nootrop virkning | |
| SE9201188D0 (sv) | Ny anvaendning | |
| ATE137973T1 (de) | Phospholipide zur behandlung der multiplen sklerose |